Download - Glenmark
Download - Glenmark
Download - Glenmark
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
NOTE Y - SEGMENT REPORTING<br />
The Chief Operating Decision Maker (“CODM”) evaluates the Group’s performance and allocates resources based on<br />
an analysis of various performance indicators by reportable segments. The Group’s reportable segments are as follows:<br />
1. India<br />
2. United States<br />
3. Latin America<br />
4. Europe<br />
5. Rest of the World<br />
The CODM reviews revenue as the performance indicator, and does not review the total assets and liabilities for each<br />
reportable segment.<br />
The measurement of each segment’s revenues, expenses and assets is consistent with the accounting policies that are<br />
used in preparation of the Company’s consolidated financial statements.<br />
Information about reportable segments<br />
Segmental Revenue<br />
Year ended<br />
31 March 2011<br />
India 9,931.68<br />
USA 8,779.16<br />
Latin America 2,490.04<br />
Europe 3,719.86<br />
Rest of the world (ROW) 4,569.96<br />
Total 29,490.70<br />
Analysis of revenue by Category<br />
Specialty: This segment includes manufacture and distribution of branded products of the Group. The Specialty business<br />
in focused on several therapeutic segments such as Dermatology, Internal medicine, Respiratory, Pediatrics, Diabetes,<br />
Gynecology, Oncology etc.<br />
Generics: This segment consists of finished pharmaceutical products ready for consumption by the patient, marketed<br />
under as generic finished dosages with therapeutic equivalence to branded formulations (generics).<br />
Out-licensing: This segment involves the discovery of new chemical entities for subsequent commercialisation and outlicensing.<br />
This segment also includes contract research services in accordance with the specific customer requirements.<br />
Revenues Gross Less Inter Net<br />
Segment<br />
Specialty 16,030.49 67.44 15,963.05<br />
Generics 12,864.48 231.93 12,632.55<br />
Out-licensing 895.10 - 895.10<br />
Total 29,790.07 299.37 29,490.70<br />
Analysis of assets by reportable segments<br />
India USA Latin Europe ROW Total<br />
America<br />
Tangible Assets 10,181.67 34.42 1,080.33 468.91 28.79 11,794.12<br />
Intangible Assets 1,698.84 740.39 2,772.67 4,450.35 61.13 9,723.38<br />
Total 21,517.50<br />
NOTE Z - OTHER FINANCIAL ASSETS<br />
Trade receivables comprise amounts receivable from the sale of goods and services. Other current assets include<br />
prepayments, input taxes, advances to vendors, accrued interest and deposits and advances receivable in cash and kind.<br />
The management consider that the carrying amount of trade and other receivables approximates their fair value.<br />
Bank balances and cash comprise cash and short-term deposits held by the group treasury function. The carrying amount<br />
of these assets approximates their fair value.<br />
Available - for - sale investments – Non-current represent investments in preferred stock of other pharmaceutical companies<br />
which present the Group with opportunity for return through dividend income and security deposits for operating leases<br />
and other services.<br />
The Investment in equity shares amounting to ` 2.68 been stated at cost less impairment charges as these are unlisted and<br />
therefore the fair value of the Group’s equity investment in this entity cannot be reliably measured.<br />
Annual Report 2010-2011 103